Difference between revisions of "Part:BBa K4768005"
Line 28: Line 28:
 
             style="width:90%;"
 
             style="width:90%;"
 
             src="https://static.igem.wiki/teams/4768/wiki/pertu-trastu/sl-pertu.png">  
 
             src="https://static.igem.wiki/teams/4768/wiki/pertu-trastu/sl-pertu.png">  
−
             <figcaption class="normal"><span class="titre-image"><i><b>Figure 1: T7Nterm-SL-Pertuzumab structure.</b></i></span></figcaption>
+
             <figcaption class="normal"><span class="titre-image"><i><b>Figure 1: Pertuzumab-SL-Nterm structure.</b></i></span></figcaption>
 
         </figure>
 
         </figure>
 
</div>
 
</div>
Line 62: Line 62:
  
 
<h2>Production</h2>
 
<h2>Production</h2>
−
<p>We first expressed part BBa_K4768005 from its DNA template using the PURE<I>free</I> 2.0 kit supplemented with SP6 RNAP. The reaction products were analyzed by SDS-PAGE. Because the theoretical molecular weight is 69 kDa, no other band from PURE system proteins was expected to migrate at this size. The protein pattern shown in Figure 4 exhibits an additional band around 69 kDa compared to the negative controls. This result indicates successful production of the full-length T7Nterm-SL-Pertuzumab in PUREfrex 2.0.</p>
+
<p>We first expressed part BBa_K4768005 from its DNA template using the PURE<I>free</I> 2.0 kit supplemented with SP6 RNAP. The reaction products were analyzed by SDS-PAGE. Because the theoretical molecular weight is 69 kDa, no other band from PURE system proteins was expected to migrate at this size. The protein pattern shown in Figure 4 exhibits an additional band around 69 kDa compared to the negative controls. This result indicates successful production of the full-length Pertuzumab-SL-Nterm in PUREfrex 2.0.</p>
  
 
<div align="center">
 
<div align="center">
Line 69: Line 69:
 
             class="d-block"
 
             class="d-block"
 
             style="width:70%;"
 
             style="width:70%;"
−
             src="https://static.igem.wiki/teams/4768/wiki/parts/pertu-pure1.jpg">  
+
             src="https://static.igem.wiki/teams/4768/wiki/module-2/pertu-image-1.png">  
−
             <figcaption class="normal"><span class="titre-image"><i><b>Figure 4: SDS-PAGE analysis (10% polyacrylamide) of T7Nterm-SL-Pertuzumab expressed in PURE system. </b>Reaction tube, T+, and T- were revealed by Instant Blue coloration.</i></span></figcaption>
+
             <figcaption class="normal"><span class="titre-image"><i><b>Figure 4: SDS-PAGE (10% polyacrylamide) analysis of Pertuzumab-SL-T7Nterm visualized by Instant Blue staining.</b> The arrowhead indicates the additional band corresponding to Pertuzumab-SL-T7Nterm (69  kDa). PURE<i>frex</i>2.0 was used. SP6 RNAP was added in the negative control (T-).  In the positive control (T+), DHFR was expressed but the band ran out of the gel due to the low molecular weight.</i></span></figcaption>
 +
        </figure>
 +
</div>
 +
 
 +
<p>Next, we produced Pertuzumab-SL-Nterm using the PURE<I>frex</I> 2.1 kit to promote disulfide bond formation due to non reducing conditions. SDS-PAGE analysis shows the expected band of the protein at 69 kDa (Figure 5).</p>
 +
 
 +
<div align="center">
 +
        <figure class="normal mx-auto">   
 +
            <img
 +
            class="d-block"
 +
            style="width:70%;"
 +
            src="https://static.igem.wiki/teams/4768/wiki/module-2/pertu-image-2.png.jpg">
 +
            <figcaption class="normal"><span class="titre-image"><i><b>Figure 5: SDS-PAGE (10% polyacrylamide) analysis of Pertuzumab-SL-T7Nterm visualized by co-translational labeling with GreenLys.</b> The arrowhead indicates the additional band corresponding to Pertuzumab-SL-T7Nterm (69  kDa). PURE<i>frex</i>2.1 was used. SP6 RNAP was added in the negative control (T-).  In the positive control (T+), DHFR was expressed but the band ran out of the gel due to the low molecular weight..</i></span></figcaption>
 
         </figure>
 
         </figure>
 
</div>
 
</div>

Revision as of 10:03, 8 October 2023


split T7 RNA polymerase (Nterm) conjugated to Pertuzumab with a soluble linker

Part for Expression of the split T7 RNA polymerase (Nterm) conjugated to Pertuzumab with a soluble linker in PURE System

Sequence and Features


Assembly Compatibility:
  • 10
    INCOMPATIBLE WITH RFC[10]
    Illegal XbaI site found at 40
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal XhoI site found at 636
  • 23
    INCOMPATIBLE WITH RFC[23]
    Illegal XbaI site found at 40
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal XbaI site found at 40
    Illegal AgeI site found at 1104
  • 1000
    INCOMPATIBLE WITH RFC[1000]
    Illegal BsaI.rc site found at 21
    Illegal SapI.rc site found at 1740



Introduction

Figure 1: Pertuzumab-SL-Nterm structure.

The CALIPSO part BBa_K4768005 is composed of the N-terminal subunit of the T7 RNA polymerase (residues 1 to 180) fused to the anti-HER2 antibody Pertuzumab through a soluble linker. This gene is under transcriptional control of an SP6 promoter and T7 terminator.

This part, coupled to the part BBa_K4768006 containing the C-terminal subunit of the T7 RNA polymerase, has been designed to develop a split T7 RNAP-based biosensor capable of recognizing HER-2, an epidermal growth factor that is overexpressed in cancer cells [1], in solution.

The HER2-induced T7 RNAP complex was designed from two existing constructs: a split T7 RNAP-based biosensor for the detection of rapamycin [2] and a split luciferase conjugated with antibodies capable of recognizing HER2 [3]. We decided to merge the relevant functionalities of these two constructs and created a new biosensor that transduces HER2 binding to gene expression activation.

Figure 2: Recognition of HER2 extracellular domain induces functional assembly of the split T7 RNA polymerase, which enables gene expression of target gene under control of a T7 promoter.

Construction

The CALIPSO part BBa_K4768005 consists in the N-terminal subunit of the T7 RNA polymerase fused to Pertuzumab, an anti-HER2 antibody, on its C-terminal domain through an 8-amino-acid linker of glycine and serine residues. The synthesis of this gBlock was made by IDT.

The gBlock was then cloned into the pET_21a(+) plasmid and transformed into Stellar competent cells. Figure 3 shows the restriction profile of the resulting clones. Clone 8 was digested using BsaI. Two bands were expected at 1.3 kb and 5.8 kb. Clones 6 and 15 were digested using EcoRV and XhoI. Two bands were expected at 2.6 kb and 4.6 kb. Only clone 8 showed the expected pattern (lane 3). Plasmids from clones 6 and 15 seemed to be the initial pET_21a(+).

Figure 3: Digestion analysis by BsaI of plasmid extracted from clone 8, and double digestion by EcoRV and XhoI of plasmids extracted from clone 6 and 15.

Production

We first expressed part BBa_K4768005 from its DNA template using the PUREfree 2.0 kit supplemented with SP6 RNAP. The reaction products were analyzed by SDS-PAGE. Because the theoretical molecular weight is 69 kDa, no other band from PURE system proteins was expected to migrate at this size. The protein pattern shown in Figure 4 exhibits an additional band around 69 kDa compared to the negative controls. This result indicates successful production of the full-length Pertuzumab-SL-Nterm in PUREfrex 2.0.

Figure 4: SDS-PAGE (10% polyacrylamide) analysis of Pertuzumab-SL-T7Nterm visualized by Instant Blue staining. The arrowhead indicates the additional band corresponding to Pertuzumab-SL-T7Nterm (69 kDa). PUREfrex2.0 was used. SP6 RNAP was added in the negative control (T-). In the positive control (T+), DHFR was expressed but the band ran out of the gel due to the low molecular weight.

Next, we produced Pertuzumab-SL-Nterm using the PUREfrex 2.1 kit to promote disulfide bond formation due to non reducing conditions. SDS-PAGE analysis shows the expected band of the protein at 69 kDa (Figure 5).

Figure 5: SDS-PAGE (10% polyacrylamide) analysis of Pertuzumab-SL-T7Nterm visualized by co-translational labeling with GreenLys. The arrowhead indicates the additional band corresponding to Pertuzumab-SL-T7Nterm (69 kDa). PUREfrex2.1 was used. SP6 RNAP was added in the negative control (T-). In the positive control (T+), DHFR was expressed but the band ran out of the gel due to the low molecular weight..

Characterisation

TXXXXXX.

Conclusion and Perspectives

TXXXXXX.

References

  1. article 1 xxxxxxxx
  2. article 2 xxxxxxx
    3.